Table 2—

Blood pressure, insulin sensitivity, and cardiovascular risk factors before and after rosiglitazone treatment

Week 0Week 16P value
24-h mean ABPM
Systolic blood pressure (mmHg)138 ± 2134 ± 2<0.01
Diastolic blood pressure (mmHg)85 ± 280 ± 2<0.0001
Daytime ABPM (0600–2300)
Systolic blood pressure (mmHg)141 ± 2137 ± 2<0.05
Diastolic blood pressure (mmHg)87 ± 283 ± 2<0.001
Nighttime ABPM (2300–0600)
Systolic blood pressure (mmHg)131 ± 3126 ± 3<0.02
Diastolic blood pressure (mmHg)80 ± 273 ± 2<0.0001
Fasting glucose (mg/dl)83 ± 282 ± 2NS
Fasting insulin (units/ml)16.1 ± 1.412.5 ± 0.9<0.01
Basal hepatic glucose output (mg · kg−1 · min−1)1.8 ± 0.11.8 ± 0.1NS
Insulin-stimulated glucose disposal (mg · kg−1 · min−1)5.0 ± 0.45.9 ± 0.5<0.001
Residual hepatic glucose output (mg · kg−1 · min−1)0.7 ± 0.10.7 ± 0.1NS
Total cholesterol (mg/dl)207 ± 7187 ± 8<0.001
 LDL cholesterol (mg/dl)129 ± 6122 ± 80.18
 HDL cholesterol (mg/dl)51 ± 346 ± 3<0.05
Triglycerides (mg/dl)134 ± 1689 ± 8<0.04
CRP (mg/dl)0.27 ± 0.050.15 ± 0.04<0.002
PAI-1 (ng/ml)16.7 ± 1.511.1 ± 1.5<0.009
  • Data are means ± SE.